Sign in Subscribe
Class action lawsuits

Securities Lawsuit Filed Against Altimmune, Inc. Over Alleged Securities Fraud

Strategic Insights

— 1 min read

Altimmune investors who were affected by alleged securities fraud between August 10, 2023 and June 25, 2025 may be entitled to compensation. The lawsuit claims that the company failed to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. As a result, the price of Altimmune's common stock declined dramatically, losing 53.2% of its value in a single day. Investors have until October 6, 2025 to request that the Court appoint them as lead plaintiff.

Key Takeaways:

  • The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025.
  • The complaint alleges that Altimmune failed to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial.
  • Despite a positive trend in fibrosis improvement, statistical significance was not met due to a higher-than-expected placebo response.
  • The company attributed the result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial.
  • The price of Altimmune's common stock declined by 53.2% in a single day, from $7.71 per share to $3.61 per share.
  • Investors have until October 6, 2025 to request that the Court appoint them as lead plaintiff.
  • The lawsuit aims to compensate investors without payment of any out-of-pocket costs or fees.

Statistics:

  • 53.2% decline in Altimmune's stock price in a single day.
  • August 10, 2023 to June 25, 2025: alleged period of securities fraud.
  • $3.61 per share: closing market price of Altimmune's stock after the decline.
  • $7.71 per share: closing market price of Altimmune's stock before the decline.
  • October 6, 2025: deadline for investors to request appointment as lead plaintiff.

Sources:

  • Levi & Korsinsky, LLP (press release)
  • GLOBE NEWSWIRE ( press release)

Read more